The transforming (onc) genes of oncogenic retroviruses share most or all of their coding sequences with normal cellular genes termed proto-onc genes. The viral genes differ from proto-onc genes in virus-specific promoters and in various point mutations and substitutions ofcell-derived coding regions. In view of the structural similarities between viral oncogenes and cellular proto-onc genes, the hypothesis has been advanced that proto-onc genes become cellular cancer genes if they have suffered mutations. Indeed, point mutations and substitutions have been observed in the proto-onc genes of some cancers. However, the hypothesis has been difficult to prove because mutated proto-onc genes from tumors do not transform diploid cells. Moreover, owing to the popularity of this hypothesis, even viral oncogenes are thought to derive transforming function from mutations of this cell-derived coding region. A competing hypothesis proposes that enhanced expression from retroviral promoters is necessary and sufficient for oncogenic function of proto-onc genes. To distinguish between these hypotheses we have tested tumorigenicity of RpSV, a synthetic retrovirus with the normal proto-src coding region in a vector derived from Rous sarcoma virus (RSV). In addition, we have tested the role of RSV-specific src point mutations on the tumorigenicity of RpSV. It was found that RpSV with an unmutated proto-src coding region is tumorigenic in chickens and that tumorigenicity is enhanced by RSV-specific src point mutations. It is concluded that retroviral promoters are essential for the transforming function of viral oncogenes and that certain point mutations merely supplement their transforming function. Thus retroviral one genes are not models for the hypothesis that mutated, but transcriptionally normal, proto-onc genes of certain tumors are cancer genes.Most or all of the coding regions of retroviral transforming (onc) genes are derived from cellular genes termed proto-onc genes (1). The viral genes differ from proto-onc genes in virus-specific promoters and various point mutations, deletions, and substitutions of their coding sequences (2). For example, the transforming src gene of Rous sarcoma virus (RSV) and of three other strains of avian sarcoma viruses differs from the proto-src gene of normal cells in (i) virusspecific promoters, (ii) a virus-specific carboxyl terminus that replaces the six carboxyl-terminal amino acids, including Tyr codon 527, of proto-src by heterologous virus-or cellderived sequences, and (iii) scattered, virus strain-specific point mutations within the 514 codons that viral src and proto-src have in common (1,3).